Submitted by aml95 on Wed, 30/10/2024 - 12:25
Semaglutide-based weight loss drugs Wegovy and Ozempic - and others like them - are being hailed as ‘revolutionary’, with the potential to improve the lives of billions. The UK government has suggested they could boost the economy by helping obese people get back to work. But current estimates suggest almost two thirds of UK adults are overweight or obese.
Can these drugs really help tackle the obesity crisis? Five University of Cambridge researchers give their views, including Professor Stephen O'Rahilly, Director of the MRC Metabolic Diseases Unit at the IMS-MRL
